Donegani E, di Summa M, Agaccio G, Comoglio C, De Paulis R, Matani A
Riv Eur Sci Med Farmacol. 1989 Apr;11(2):143-8.
Clinical effectiveness of Aztreonam was studied. This new monobactam antimicrobial agent was tasted in the treatment of post-operative infectious complications of cardiac surgical sternal wounds. Ten patients (4 men and 6 women, age range 20 to 68 years) were entered into the study. All had a Pseudomonas aeruginosa infection of sternum or sternum and ribs and all underwent an extensive regional surgery of the infection wound and received a topical and/or IV treatment with Aztreonam. In all cases we obtained a satisfactory result, with complete eradication of the infection. Both local and systemic tolerance to the drug were excellent and no side-effect was registered. Therefore Aztreonam can be considered an active and safe antibiotic for the treatment of sternal and/or costal postsurgical infections by Pseudomonas aeruginosa.
研究了氨曲南的临床疗效。这种新型单环β-内酰胺类抗菌剂用于治疗心脏外科胸骨伤口术后感染并发症。10名患者（4名男性和6名女性，年龄范围20至68岁）进入该研究。所有患者均患有胸骨或胸骨与肋骨的铜绿假单胞菌感染，均接受了感染伤口的广泛局部手术，并接受了氨曲南的局部和/或静脉治疗。在所有病例中，我们都取得了满意的结果，感染被完全根除。药物的局部和全身耐受性都非常好，未记录到副作用。因此，氨曲南可被认为是治疗铜绿假单胞菌引起的胸骨和/或肋骨术后感染的一种有效且安全的抗生素。
